Skip to main content
. 2018 May 29;6(3):321–344. doi: 10.1016/j.jcmgh.2018.05.009

Figure 6.

Figure 6

Effects of the NK2R antagonist GR 159897 on colonic inflammation and TAC1 mRNA levels during acute colitis and recovery in mice. (A) Schematic representation of the timeline of treatments during colitis. (B) Weight loss pattern after induction of DNBS colitis in mice (n = 5–16 mice; 2-way analysis of variance with multiple comparisons; ∗∗∗P < .001; ****P < .0001). Note that inflamed mice treated with GR 159897 recover normal body weight sooner than inflamed mice treated with vehicle. (C) GR 159897 did not modify macroscopic damage to the colon at 48 hours or 3 weeks after induction of DNBS colitis in mice (n = 5–16 mice; 2-way analysis of variance with multiple comparisons; ****P < .0001). (D) GR 159897 did not modify histology scoring to the colon at 24 hours after induction of DNBS colitis in mice (n = 3–4 mice; 2-way analysis of variance with multiple comparisons; ****P < .0001). (E) TAC1 mRNA levels (normalized to glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) in the distal colon myenteric plexus of healthy (vehicle) and inflamed (DNBS) mice treated with vehicle or GR 159897 at 48 hours or 3 weeks after induction of DNBS colitis (n = 4–7 mice; 2-way analysis of variance with multiple comparisons; *P = .0368).